A drug intervention study in atherosclerotic mice demonstrated that an orally active small-molecule inhibitor of FABP4, BMS309403 (see also “Known drugs and compounds inhibiting FABP4”), was an effective therapeutic agent against severe atherosclerosis and type 2 diabetes in mouse models [42]. Here, FABP4 is linked to atherosclerosis.